APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease CDMO

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neurodegenerative Disease CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174196870315 April 2026196 pages

Choose your research edition.

Industry ResearchNeurodegenerative Disease CDMO Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease CDMO Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease CDMO Market Analysis and Forecast 2026-2032258 pages · $4,950 USD

Market perspective

The global Neurodegenerative Disease CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurodegenerative Disease CDMO include AC Immune, Alterity Therapeutics, Biogen, Charles River Laboratories, Coave Therapeutics, Sysmex Corp, Donanemab, Eisai and Fujirebio Holdings, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Neurodegenerative Disease CDMO market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurodegenerative Disease CDMO and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurodegenerative Disease CDMO revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neurodegenerative Disease CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurodegenerative Disease CDMO Segment by Company

AC Immune

Alterity Therapeutics

Biogen

Charles River Laboratories

Coave Therapeutics

Sysmex Corp

Donanemab

Eisai

Fujirebio Holdings

GenSight Biologics

Neuropore Therapies

Nevrargenics

PPD

Samsung Biologics

Sanofi(Vigil Neuroscience)

Neurodegenerative Disease CDMO Segment by Type

Small Molecule Drug CDMO

Biopharmaceutical CDMO

Cell and Gene Therapy (CGT) CDMO

OtherS

Neurodegenerative Disease CDMO Segment by Application

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Progressive Supranuclear Palsy (PSP)

Others

Neurodegenerative Disease CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neurodegenerative Disease CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Disease CDMO industry.

Chapter 3: Detailed analysis of Neurodegenerative Disease CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Disease CDMOrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Small Molecule Drug CDMO Table 3. Key Players of Biopharmaceutical CDMO Table 4. Key Players of Cell and Gene Therapy (CGT) CDMO Table 3. Key Players of OtherS Table 4. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Alzheimer's Disease Table 6. Key Players of Parkinson's Disease Table 7. Key Players of Huntington's Disease Table 8. Key Players of Amyotrophic Lateral Sclerosis (ALS) Table 9. Key Players of Multiple System Atrophy (MSA) Table 10. Key Players of Progressive Supranuclear Palsy (PSP) Table 11. Key Players of Others Table 12. Global Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Neurodegenerative Disease CDMO Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Neurodegenerative Disease CDMO Market Share by Region (2021-2026) Table 15. Global Neurodegenerative Disease CDMO Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Neurodegenerative Disease CDMO Market Share by Region (2027-2032) Table 17. Neurodegenerative Disease CDMO Industry Trends Table 18. Neurodegenerative Disease CDMO Industry Drivers Table 19. Neurodegenerative Disease CDMO Industry Opportunities and Challenges Table 20. Neurodegenerative Disease CDMO Industry Restraints Table 21. Global Neurodegenerative Disease CDMO Revenue by Company (US$ Million) & (2021-2026) Table 22. Global Neurodegenerative Disease CDMO Revenue Market Share by Company (2021-2026) Table 23. Global Neurodegenerative Disease CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 24. Global Neurodegenerative Disease CDMO Key Company Head Office and Area Served Table 25. Global Neurodegenerative Disease CDMO Company, Product Type & Application Table 26. Global Neurodegenerative Disease CDMO Company Establishment Date Table 27. Global Company Market Concentration Ratio (CR5 and HHI) Table 28. Global Neurodegenerative Disease CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 29. Global Neurodegenerative Disease CDMO Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million) Table 31. Global Neurodegenerative Disease CDMO Market Size by Type (2027-2032) & (US$ Million) Table 32. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2021-2026) Table 33. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2027-2032) Table 34. Global Neurodegenerative Disease CDMO Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million) Table 36. Global Neurodegenerative Disease CDMO Market Size by Application (2027-2032) & (US$ Million) Table 37. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2021-2026) Table 38. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2027-2032) Table 39. AC Immune Company Information Table 40. AC Immune Business Overview Table 41. AC Immune Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. AC Immune Neurodegenerative Disease CDMO Product Portfolio Table 43. AC Immune Recent Development Table 44. Alterity Therapeutics Company Information Table 45. Alterity Therapeutics Business Overview Table 46. Alterity Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Alterity Therapeutics Neurodegenerative Disease CDMO Product Portfolio Table 48. Alterity Therapeutics Recent Development Table 49. Biogen Company Information Table 50. Biogen Business Overview Table 51. Biogen Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Biogen Neurodegenerative Disease CDMO Product Portfolio Table 53. Biogen Recent Development Table 54. Charles River Laboratories Company Information Table 55. Charles River Laboratories Business Overview Table 56. Charles River Laboratories Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Charles River Laboratories Neurodegenerative Disease CDMO Product Portfolio Table 58. Charles River Laboratories Recent Development Table 59. Coave Therapeutics Company Information Table 60. Coave Therapeutics Business Overview Table 61. Coave Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Coave Therapeutics Neurodegenerative Disease CDMO Product Portfolio Table 63. Coave Therapeutics Recent Development Table 64. Sysmex Corp Company Information Table 65. Sysmex Corp Business Overview Table 66. Sysmex Corp Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Sysmex Corp Neurodegenerative Disease CDMO Product Portfolio Table 68. Sysmex Corp Recent Development Table 69. Donanemab Company Information Table 70. Donanemab Business Overview Table 71. Donanemab Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Donanemab Neurodegenerative Disease CDMO Product Portfolio Table 73. Donanemab Recent Development Table 74. Eisai Company Information Table 75. Eisai Business Overview Table 76. Eisai Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Eisai Neurodegenerative Disease CDMO Product Portfolio Table 78. Eisai Recent Development Table 79. Fujirebio Holdings Company Information Table 80. Fujirebio Holdings Business Overview Table 81. Fujirebio Holdings Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Fujirebio Holdings Neurodegenerative Disease CDMO Product Portfolio Table 83. Fujirebio Holdings Recent Development Table 84. GenSight Biologics Company Information Table 85. GenSight Biologics Business Overview Table 86. GenSight Biologics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. GenSight Biologics Neurodegenerative Disease CDMO Product Portfolio Table 88. GenSight Biologics Recent Development Table 89. Neuropore Therapies Company Information Table 90. Neuropore Therapies Business Overview Table 91. Neuropore Therapies Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. Neuropore Therapies Neurodegenerative Disease CDMO Product Portfolio Table 93. Neuropore Therapies Recent Development Table 94. Nevrargenics Company Information Table 95. Nevrargenics Business Overview Table 96. Nevrargenics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. Nevrargenics Neurodegenerative Disease CDMO Product Portfolio Table 98. Nevrargenics Recent Development Table 99. PPD Company Information Table 100. PPD Business Overview Table 101. PPD Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 102. PPD Neurodegenerative Disease CDMO Product Portfolio Table 103. PPD Recent Development Table 104. Samsung Biologics Company Information Table 105. Samsung Biologics Business Overview Table 106. Samsung Biologics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 107. Samsung Biologics Neurodegenerative Disease CDMO Product Portfolio Table 108. Samsung Biologics Recent Development Table 109. Sanofi(Vigil Neuroscience) Company Information Table 110. Sanofi(Vigil Neuroscience) Business Overview Table 111. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 112. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Portfolio Table 113. Sanofi(Vigil Neuroscience) Recent Development Table 114. North America Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million) Table 115. North America Neurodegenerative Disease CDMO Market Size by Type (2027-2032) & (US$ Million) Table 116. North America Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million) Table 117. North America Neurodegenerative Disease CDMO Market Size by Application (2027-2032) & (US$ Million) Table 118. North America Neurodegenerative Disease CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America Neurodegenerative Disease CDMO Market Size by Country (2021-2026) Table 120. North America Neurodegenerative Disease CDMO Market Size by Country (2027-2032) Table 121. Europe Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million) Table 122. Europe Neurodegenerative Disease CDMO Market Size by Type (2027-2032) & (US$ Million) Table 123. Europe Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million) Table 124. Europe Neurodegenerative Disease CDMO Market Size by Application (2027-2032) & (US$ Million) Table 125. Europe Neurodegenerative Disease CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Europe Neurodegenerative Disease CDMO Market Size by Country (2021-2026) Table 127. Europe Neurodegenerative Disease CDMO Market Size by Country (2027-2032) Table 128. China Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million) Table 129. China Neurodegenerative Disease CDMO Market Size by Type (2027-2032) & (US$ Million) Table 130. China Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million) Table 131. China Neurodegenerative Disease CDMO Market Size by Application (2027-2032) & (US$ Million) Table 132. Asia Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million) Table 133. Asia Neurodegenerative Disease CDMO Market Size by Type (2027-2032) & (US$ Million) Table 134. Asia Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million) Table 135. Asia Neurodegenerative Disease CDMO Market Size by Application (2027-2032) & (US$ Million) Table 136. Asia Neurodegenerative Disease CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Asia Neurodegenerative Disease CDMO Market Size by Country (2021-2026) Table 138. Asia Neurodegenerative Disease CDMO Market Size by Country (2027-2032) Table 139. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Type (2021-2026) & (US$ Million) Table 140. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Type (2027-2032) & (US$ Million) Table 141. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Application (2021-2026) & (US$ Million) Table 142. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Application (2027-2032) & (US$ Million) Table 143. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2021-2026) Table 145. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2027-2032) Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Neurodegenerative Disease CDMO Product Image Figure 2. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neurodegenerative Disease CDMO Market Share by Type: 2025 VS 2032 Figure 4. Small Molecule Drug CDMO Image Figure 5. Biopharmaceutical CDMO Image Figure 6. Cell and Gene Therapy (CGT) CDMO Image Figure 7. OtherS Image Figure 8. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Neurodegenerative Disease CDMO Market Share by Application: 2025 VS 2032 Figure 10. Alzheimer's Disease Image Figure 11. Parkinson's Disease Image Figure 12. Huntington's Disease Image Figure 13. Amyotrophic Lateral Sclerosis (ALS) Image Figure 14. Multiple System Atrophy (MSA) Image Figure 15. Progressive Supranuclear Palsy (PSP) Image Figure 16. Others Image Figure 17. Global Neurodegenerative Disease CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 19. Global Neurodegenerative Disease CDMO Market Share by Region: 2025 VS 2032 Figure 20. Years Considered Figure 21. Global Neurodegenerative Disease CDMO Market Share by Players in 2025 Figure 22. Global Top 5 and 10 Neurodegenerative Disease CDMO Players Market Share by Revenue in 2025 Figure 23. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. Global Neurodegenerative Disease CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2021-2032) Figure 26. Global Neurodegenerative Disease CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2021-2032) Figure 28. North America Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 29. North America Neurodegenerative Disease CDMO Market Share by Type (2021-2032) Figure 30. North America Neurodegenerative Disease CDMO Market Share by Application (2021-2032) Figure 31. North America Neurodegenerative Disease CDMO Market Share by Country (2021-2032) Figure 32. United States Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 33. Canada Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 34. Mexico Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 35. Europe Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 36. Europe Neurodegenerative Disease CDMO Market Share by Type (2021-2032) Figure 37. Europe Neurodegenerative Disease CDMO Market Share by Application (2021-2032) Figure 38. Europe Neurodegenerative Disease CDMO Market Share by Country (2021-2032) Figure 39. Germany Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 40. France Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 41. U.K. Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 42. Italy Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 43. Russia Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 44. Nordic Countries Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 45. China Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 46. China Neurodegenerative Disease CDMO Market Share by Type (2021-2032) Figure 47. China Neurodegenerative Disease CDMO Market Share by Application (2021-2032) Figure 48. Asia Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 49. Asia Neurodegenerative Disease CDMO Market Share by Type (2021-2032) Figure 50. Asia Neurodegenerative Disease CDMO Market Share by Application (2021-2032) Figure 51. Asia Neurodegenerative Disease CDMO Market Share by Country (2021-2032) Figure 52. Japan Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 53. South Korea Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 54. Taiwan Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 55. Southeast Asia Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 56. India Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 57. Australia Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 58. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 59. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Share by Type (2021-2032) Figure 60. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Share by Application (2021-2032) Figure 61. South America, Middle East & Africa Neurodegenerative Disease CDMO Market Share by Country (2021-2032) Figure 62. Brazil Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 63. South Africa Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 64. Saudi Arabia Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 65. Turkey Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 66. Argentina Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 67. UAE Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 68. Egypt Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 69. Chile Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule Drug CDMO
  • Biopharmaceutical CDMO
  • Cell and Gene Therapy (CGT) CDMO
  • OtherS
Applications
  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple System Atrophy (MSA)
  • Progressive Supranuclear Palsy (PSP)
  • Others
Companies covered
  • AC Immune
  • Alterity Therapeutics
  • Biogen
  • Charles River Laboratories
  • Coave Therapeutics
  • Sysmex Corp
  • Donanemab
  • Eisai
  • Fujirebio Holdings
  • GenSight Biologics
  • Neuropore Therapies
  • Nevrargenics
  • PPD
  • Samsung Biologics
  • Sanofi(Vigil Neuroscience)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Small Molecule Drug CDMO
  5. 1.2.3 Biopharmaceutical CDMO
  6. 1.2.4 Cell and Gene Therapy (CGT) CDMO
  7. 1.2.5 OtherS
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Alzheimer's Disease
  11. 1.3.3 Parkinson's Disease
  12. 1.3.4 Huntington's Disease
  13. 1.3.5 Amyotrophic Lateral Sclerosis (ALS)
  14. 1.3.6 Multiple System Atrophy (MSA)
  15. 1.3.7 Progressive Supranuclear Palsy (PSP)
  16. 1.3.8 Others
  17. 1.4 Global Market Growth Prospects
  18. 1.5 Global Neurodegenerative Disease CDMO Growth Trends by Region
  19. 1.5.1 Global Neurodegenerative Disease CDMO Market Size by Region: 2021 VS 2025 VS 2032
  20. 1.5.2 Neurodegenerative Disease CDMO Market Size by Region (2021-2026)
  21. 1.5.3 Neurodegenerative Disease CDMO Market Size by Region (2027-2032)
  22. 1.6 Assumptions and Limitations
  23. 1.7 Study Goals and Objectives
  24. 1.8 Years Considered
2 Global Neurodegenerative Disease CDMO Market Dynamics
  1. 2.1 Neurodegenerative Disease CDMO Industry Trends
  2. 2.2 Neurodegenerative Disease CDMO Industry Drivers
  3. 2.3 Neurodegenerative Disease CDMO Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Disease CDMO Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neurodegenerative Disease CDMO Revenue by Company (2021-2026)
  2. 3.2 Global Neurodegenerative Disease CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neurodegenerative Disease CDMO Key Company Head office and Area Served
  4. 3.4 Global Neurodegenerative Disease CDMO Company, Product Type & Application
  5. 3.5 Global Neurodegenerative Disease CDMO Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neurodegenerative Disease CDMO Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neurodegenerative Disease CDMO Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neurodegenerative Disease CDMO Tier 1, Tier 2, and Tier 3
4 Neurodegenerative Disease CDMO Market by Type
  1. 4.1 Global Neurodegenerative Disease CDMO Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neurodegenerative Disease CDMO Market Size by Type (2021-2032)
  3. 4.3 Global Neurodegenerative Disease CDMO Market Size Share by Type (2021-2032)
5 Neurodegenerative Disease CDMO Market by Application
  1. 5.1 Global Neurodegenerative Disease CDMO Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neurodegenerative Disease CDMO Market Size by Application (2021-2032)
  3. 5.3 Global Neurodegenerative Disease CDMO Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 AC Immune
  2. 6.1.1 AC Immune Company Information
  3. 6.1.2 AC Immune Business Overview
  4. 6.1.3 AC Immune Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 AC Immune Neurodegenerative Disease CDMO Product Portfolio
  6. 6.1.5 AC Immune Recent Developments
  7. 6.2 Alterity Therapeutics
  8. 6.2.1 Alterity Therapeutics Company Information
  9. 6.2.2 Alterity Therapeutics Business Overview
  10. 6.2.3 Alterity Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Alterity Therapeutics Neurodegenerative Disease CDMO Product Portfolio
  12. 6.2.5 Alterity Therapeutics Recent Developments
  13. 6.3 Biogen
  14. 6.3.1 Biogen Company Information
  15. 6.3.2 Biogen Business Overview
  16. 6.3.3 Biogen Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Biogen Neurodegenerative Disease CDMO Product Portfolio
  18. 6.3.5 Biogen Recent Developments
  19. 6.4 Charles River Laboratories
  20. 6.4.1 Charles River Laboratories Company Information
  21. 6.4.2 Charles River Laboratories Business Overview
  22. 6.4.3 Charles River Laboratories Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Charles River Laboratories Neurodegenerative Disease CDMO Product Portfolio
  24. 6.4.5 Charles River Laboratories Recent Developments
  25. 6.5 Coave Therapeutics
  26. 6.5.1 Coave Therapeutics Company Information
  27. 6.5.2 Coave Therapeutics Business Overview
  28. 6.5.3 Coave Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Coave Therapeutics Neurodegenerative Disease CDMO Product Portfolio
  30. 6.5.5 Coave Therapeutics Recent Developments
  31. 6.6 Sysmex Corp
  32. 6.6.1 Sysmex Corp Company Information
  33. 6.6.2 Sysmex Corp Business Overview
  34. 6.6.3 Sysmex Corp Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Sysmex Corp Neurodegenerative Disease CDMO Product Portfolio
  36. 6.6.5 Sysmex Corp Recent Developments
  37. 6.7 Donanemab
  38. 6.7.1 Donanemab Company Information
  39. 6.7.2 Donanemab Business Overview
  40. 6.7.3 Donanemab Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Donanemab Neurodegenerative Disease CDMO Product Portfolio
  42. 6.7.5 Donanemab Recent Developments
  43. 6.8 Eisai
  44. 6.8.1 Eisai Company Information
  45. 6.8.2 Eisai Business Overview
  46. 6.8.3 Eisai Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Eisai Neurodegenerative Disease CDMO Product Portfolio
  48. 6.8.5 Eisai Recent Developments
  49. 6.9 Fujirebio Holdings
  50. 6.9.1 Fujirebio Holdings Company Information
  51. 6.9.2 Fujirebio Holdings Business Overview
  52. 6.9.3 Fujirebio Holdings Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Fujirebio Holdings Neurodegenerative Disease CDMO Product Portfolio
  54. 6.9.5 Fujirebio Holdings Recent Developments
  55. 6.10 GenSight Biologics
  56. 6.10.1 GenSight Biologics Company Information
  57. 6.10.2 GenSight Biologics Business Overview
  58. 6.10.3 GenSight Biologics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 GenSight Biologics Neurodegenerative Disease CDMO Product Portfolio
  60. 6.10.5 GenSight Biologics Recent Developments
  61. 6.11 Neuropore Therapies
  62. 6.11.1 Neuropore Therapies Company Information
  63. 6.11.2 Neuropore Therapies Business Overview
  64. 6.11.3 Neuropore Therapies Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Neuropore Therapies Neurodegenerative Disease CDMO Product Portfolio
  66. 6.11.5 Neuropore Therapies Recent Developments
  67. 6.12 Nevrargenics
  68. 6.12.1 Nevrargenics Company Information
  69. 6.12.2 Nevrargenics Business Overview
  70. 6.12.3 Nevrargenics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Nevrargenics Neurodegenerative Disease CDMO Product Portfolio
  72. 6.12.5 Nevrargenics Recent Developments
  73. 6.13 PPD
  74. 6.13.1 PPD Company Information
  75. 6.13.2 PPD Business Overview
  76. 6.13.3 PPD Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 PPD Neurodegenerative Disease CDMO Product Portfolio
  78. 6.13.5 PPD Recent Developments
  79. 6.14 Samsung Biologics
  80. 6.14.1 Samsung Biologics Company Information
  81. 6.14.2 Samsung Biologics Business Overview
  82. 6.14.3 Samsung Biologics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Samsung Biologics Neurodegenerative Disease CDMO Product Portfolio
  84. 6.14.5 Samsung Biologics Recent Developments
  85. 6.15 Sanofi(Vigil Neuroscience)
  86. 6.15.1 Sanofi(Vigil Neuroscience) Company Information
  87. 6.15.2 Sanofi(Vigil Neuroscience) Business Overview
  88. 6.15.3 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Portfolio
  90. 6.15.5 Sanofi(Vigil Neuroscience) Recent Developments
7 North America
  1. 7.1 North America Neurodegenerative Disease CDMO Market Size (2021-2032)
  2. 7.2 North America Neurodegenerative Disease CDMO Market Size by Type
  3. 7.2.1 North America Neurodegenerative Disease CDMO Market Size by Type (2021-2026)
  4. 7.2.2 North America Neurodegenerative Disease CDMO Market Size by Type (2027-2032)
  5. 7.2.3 North America Neurodegenerative Disease CDMO Market Share by Type (2021-2032)
  6. 7.3 North America Neurodegenerative Disease CDMO Market Size by Application
  7. 7.3.1 North America Neurodegenerative Disease CDMO Market Size by Application (2021-2026)
  8. 7.3.2 North America Neurodegenerative Disease CDMO Market Size by Application (2027-2032)
  9. 7.3.3 North America Neurodegenerative Disease CDMO Market Share by Application (2021-2032)
  10. 7.4 North America Neurodegenerative Disease CDMO Market Size by Country
  11. 7.4.1 North America Neurodegenerative Disease CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
  13. 7.4.3 North America Neurodegenerative Disease CDMO Market Size by Country (2027-2032)
  14. 7.4.4 North America Neurodegenerative Disease CDMO Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neurodegenerative Disease CDMO Market Size (2021-2032)
  2. 8.2 Europe Neurodegenerative Disease CDMO Market Size by Type
  3. 8.2.1 Europe Neurodegenerative Disease CDMO Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neurodegenerative Disease CDMO Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neurodegenerative Disease CDMO Market Share by Type (2021-2032)
  6. 8.3 Europe Neurodegenerative Disease CDMO Market Size by Application
  7. 8.3.1 Europe Neurodegenerative Disease CDMO Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neurodegenerative Disease CDMO Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neurodegenerative Disease CDMO Market Share by Application (2021-2032)
  10. 8.4 Europe Neurodegenerative Disease CDMO Market Size by Country
  11. 8.4.1 Europe Neurodegenerative Disease CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neurodegenerative Disease CDMO Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neurodegenerative Disease CDMO Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neurodegenerative Disease CDMO Market Size (2021-2032)
  2. 9.2 China Neurodegenerative Disease CDMO Market Size by Type
  3. 9.2.1 China Neurodegenerative Disease CDMO Market Size by Type (2021-2026)
  4. 9.2.2 China Neurodegenerative Disease CDMO Market Size by Type (2027-2032)
  5. 9.2.3 China Neurodegenerative Disease CDMO Market Share by Type (2021-2032)
  6. 9.3 China Neurodegenerative Disease CDMO Market Size by Application
  7. 9.3.1 China Neurodegenerative Disease CDMO Market Size by Application (2021-2026)
  8. 9.3.2 China Neurodegenerative Disease CDMO Market Size by Application (2027-2032)
  9. 9.3.3 China Neurodegenerative Disease CDMO Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neurodegenerative Disease CDMO Market Size (2021-2032)
  2. 10.2 Asia Neurodegenerative Disease CDMO Market Size by Type
  3. 10.2.1 Asia Neurodegenerative Disease CDMO Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neurodegenerative Disease CDMO Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neurodegenerative Disease CDMO Market Share by Type (2021-2032)
  6. 10.3 Asia Neurodegenerative Disease CDMO Market Size by Application
  7. 10.3.1 Asia Neurodegenerative Disease CDMO Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neurodegenerative Disease CDMO Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neurodegenerative Disease CDMO Market Share by Application (2021-2032)
  10. 10.4 Asia Neurodegenerative Disease CDMO Market Size by Country
  11. 10.4.1 Asia Neurodegenerative Disease CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neurodegenerative Disease CDMO Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neurodegenerative Disease CDMO Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neurodegenerative Disease CDMO Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst